For regulatory and clinical teams working on GLP-1 receptor agonists or GIP/GLP-1 co-agonists, the class carries a highly conserved safety profile that FDA has applied consistently from the earliest agents through the most recent approvals. Understanding which nonclinical signals, boxed warnings, and labeled risks recur across the class—and how FDA has framed them—is essential for anticipating labeling expectations, designing toxicology and safety programs, and benchmarking a candidate against established precedent.
The analysis below draws on FDA prescribing information and review documents for the marketed GLP-1 and GIP/GLP-1 agents, including exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide, and tirzepatide. It maps the patterns that repeat across animal toxicology studies, boxed warnings, the Warnings and Precautions section, and the adverse-reaction profile, with each pattern tied back to the specific labeling and reviews in which it appears.
Want Rhizome's help on your own question? Try it for free.
Recurring safety and toxicity findings across FDA reviews and labeling for GLP-1 receptor agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists, and the GIP/GLP-1 co-agonist tirzepatide, share a strikingly consistent safety architecture across their FDA prescribing information and review documents. The same boxed warning, the same nonclinical carcinogenicity signal, the same core Warnings and Precautions, and the same gastrointestinal adverse-reaction profile recur from the earliest product (exenatide) to the most recent (tirzepatide). The patterns below are drawn from the labeling and FDA reviews for exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), albiglutide (Tanzeum), dulaglutide (Trulicity), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound).
Thyroid C-cell tumors: the class boxed warning
The defining class-level safety signal is the boxed warning for thyroid C-cell tumors, carried by essentially every long-acting agent. The warning follows a near-identical template: the drug causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures, and it is unknown whether the drug causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans because the human relevance of the rodent findings has not been determined. This language appears verbatim in structure for semaglutide 113114117118120123126, liraglutide 516517518520521522523, dulaglutide 197204, exenatide extended-release 144146150153159, tirzepatide 288290293370384386, and albiglutide 137140136.
Two consequences flow directly from this warning across every product carrying it:
- Contraindication. These agents are contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 113516144288137.
- Counseling and the limits of monitoring. Labels direct clinicians to counsel patients on the symptoms of thyroid tumors, and several note that routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value for early detection in patients treated with these drugs 326146.
Not every product frames the signal identically. Exenatide immediate-release (Byetta) states more narrowly that it has been associated with thyroid C-cell tumors in animal studies, with the human-relevance question left open 342. Albiglutide is a special case: carcinogenicity could not be assessed in rodents because the animals rapidly developed drug-clearing anti-drug antibodies, so its boxed warning rests on the rodent findings for the GLP-1 class as a whole rather than on albiglutide-specific tumor data 128129130136137. Lixisenatide is the notable divergence discussed below.
Animal toxicology: what the rodent carcinogenicity studies actually showed
The nonclinical carcinogenicity data underpinning the boxed warning show a consistent species and lesion pattern across the class.
Lesion type and species. The recurring finding is thyroid C-cell adenomas and carcinomas in rats and mice, dose-related and treatment-duration-dependent, at clinically relevant exposures. This is documented for semaglutide (mice and rats, adenomas and carcinomas after lifetime exposure) 105106107108109110111112, liraglutide (rats and mice, both sexes, with malignant carcinomas detected) 518519520521522, and exenatide extended-release (dose-related increase in both sexes of rats, with a statistically significant rise in malignant carcinomas in females at roughly 25-fold clinical exposure) 144145146150151153159.
Exposure-response detail from the reviews. The FDA nonclinical reviews provide granular dose margins:
- Liraglutide. In the 2-year rat study, focal C-cell hyperplasia occurred at the lowest-observed-effect level, C-cell adenomas increased above 0.25 mg/kg/day (males) and 0.075 mg/kg/day (females), and carcinomas exceeded concurrent and historical controls; a statistically significant increase in cancer was seen at roughly 8-times clinical exposure 512518. The CD-1 mouse study showed a dose-related increase in benign C-cell adenomas at 1.0 and 3.0 mg/kg/day and malignant carcinomas in 3% of high-dose females 207.
- Dulaglutide. Rat C-cell adenomas increased above 0.5 mg/kg (about 7x clinical AUC), with a slight numerical carcinoma increase at 5 mg/kg (about 58x clinical AUC); the no-effect level was 0.05 mg/kg (0.5x clinical AUC) 192.
- Exenatide. In the 104-week rat study benign C-cell adenomas rose in females at all doses (14%, 11%, 23% versus 8%/5% controls) at 5 to 130 times clinical exposure, while the 104-week mouse study showed no tumor signal up to 95x exposure 333337339341342.
- Tirzepatide. A 2-year rat carcinogenicity study produced dose-dependent C-cell hyperplasia, adenomas, and carcinomas in both sexes at clinically relevant exposures 279282283.
Species that did not show the signal. Several programs included non-rodent or transgenic data that did not reproduce the tumor finding, which is central to the "human relevance not determined" language. In dulaglutide's TgHras transgenic mouse study there were no drug-related neoplasms at the highest dose, and a 1-year cynomolgus monkey study at 474x exposure showed no C-cell hyperplasia or tumors 192196. Albiglutide produced no thyroid C-cell proliferation in a 52-week monkey study at 75x clinical exposure 127. The tirzepatide review notes that human relevance is unclear because of species-specific differences in GLP-1 receptor expression and activation on thyroid C-cells 280282.
Recurring Warnings and Precautions
Below the boxed warning, a common set of Warnings and Precautions recurs with remarkable consistency across the class.
Acute pancreatitis. Every product warns of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing forms, with instructions to monitor for persistent severe abdominal pain, discontinue if pancreatitis is suspected, and not restart if confirmed 387452359151221. This is uniform from exenatide 1524 through semaglutide 387388, liraglutide 452453, dulaglutide 359363, tirzepatide 15, lixisenatide 6264, and albiglutide 221226.
Acute gallbladder / biliary disease. Acute gallbladder disease (cholelithiasis, cholecystitis, biliary colic) is warned for across most of the class, with gallbladder studies indicated if cholelithiasis is suspected 40141846835819173. It is present for both semaglutide products 401418, liraglutide 468471, dulaglutide 358361, exenatide 1921, tirzepatide 17, and lixisenatide 7374. It was not found in the Tanzeum rows [as noted, absent from albiglutide labeling reviewed].
Acute kidney injury. Postmarketing acute kidney injury and worsening chronic renal failure, sometimes requiring hemodialysis, recur across the class and are consistently linked to volume depletion from nausea, vomiting, and diarrhea. This appears for semaglutide 388392, liraglutide 452453, dulaglutide 358359, exenatide (including reports requiring hemodialysis or transplantation) 151718, tirzepatide 12, lixisenatide 6264, and albiglutide 237240.
Hypoglycemia with insulin secretagogues or insulin. A uniform warning across the class is the increased risk of hypoglycemia, including severe hypoglycemia, when these agents are combined with a sulfonylurea (or other insulin secretagogue) or insulin, with a recommendation to lower the concomitant agent's dose 38745235815162221. The liraglutide label additionally flags higher hypoglycemia risk in pediatric patients 10 years and older regardless of background therapy 468.
Hypersensitivity reactions. Serious hypersensitivity reactions, specifically anaphylaxis and angioedema, recur across the class, with instructions to discontinue and, in most labels, a contraindication after a prior serious reaction to the drug 38845235815162221. Several labels advise caution in patients with prior anaphylaxis or angioedema to another GLP-1 receptor agonist 35842.
Diabetic retinopathy complications. This warning is concentrated in the type 2 diabetes indications and is tied to rapid glucose lowering. Semaglutide labels cite more retinopathy events versus placebo in a 2-year trial 387424, dulaglutide cites complications in its cardiovascular outcomes trial 358361, and tirzepatide carries a comparable warning 17. It also appears in the tirzepatide obesity product for patients with type 2 diabetes 244245.
Suicidal behavior and ideation. This warning is specific to the chronic weight-management products rather than the diabetes labels. It appears in the Saxenda (liraglutide) 537542543 and Zepbound (tirzepatide) 247248249 Warnings and Precautions. It was not present in the diabetes-label rows reviewed.
Product-specific additions. A handful of warnings are narrower. Saxenda carries a heart-rate-increase warning 534535543. The weight-management and lixisenatide labels warn of severe gastrointestinal adverse reactions and are not recommended in patients with severe gastroparesis 42554373. Adlyxin uniquely lists immunogenicity (anti-lixisenatide antibodies associated with more allergic and injection-site reactions) and pulmonary aspiration during general anesthesia or deep sedation 70737475.
Adverse reactions: gastrointestinal dominance
The adverse-reaction profile is overwhelmingly gastrointestinal across the class: nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, and dyspepsia are the most common reactions in nearly every label.
Incidence scales with dose and is markedly higher in the chronic weight-management indications, where doses are higher, than in the diabetes indications:
- Semaglutide: Ozempic (T2D) nausea 15.8% to 20.3%, vomiting 5.0% to 9.2%, diarrhea about 8.5% 168; Wegovy (obesity) nausea 44%, diarrhea 30%, vomiting 24%, constipation 24% 259261263. Overall GI reactions reached 32.7% to 36.4% on Ozempic versus 15.3% on placebo 168.
- Tirzepatide: Mounjaro (T2D) nausea 12% to 18%, diarrhea 12% to 17% across the 5 to 15 mg doses 502503505; Zepbound (obesity) nausea about 25% to 29%, diarrhea 19% to 23%, with overall GI reactions of roughly 56% versus 30% on placebo, concentrated during dose escalation 344345356.
- Liraglutide: Victoza (T2D) nausea about 18% to 28%, with overall GI reactions about 41% versus 17% for comparator 547546559; Saxenda (obesity) nausea 39.3%, diarrhea 20.9%, constipation 19.4%, vomiting 15.7% 587590599.
- Dulaglutide: nausea 12.4% to 21.1%, diarrhea 8.9% to 12.6%, vomiting 6.0% to 12.7% 577578581.
- Exenatide: Byetta nausea around 40% to 44%, vomiting 13% to 18%, diarrhea 13% to 18% 879285; the extended-release formulations shift toward injection-site reactions, with Bydureon BCISE injection-site nodule about 10.5% and nausea about 8.2% 405408.
- Lixisenatide: nausea about 25%, vomiting about 10%, diarrhea about 8% 564.
Injection-site reactions are prominent for the depot and older injectable formulations: Bydureon (injection-site pruritus and nodules) 405407, Saxenda (about 13.9%) 587590, and Tanzeum (about 10.5%) 443445.
Albiglutide is the adverse-reaction outlier. Rather than GI symptoms dominating, its most common reactions were upper respiratory tract infection (14.2%), diarrhea (13.1%), nausea (11.1%), and injection-site reaction (10.5%), with a respiratory cluster (cough, sinusitis, influenza) not seen with the other agents 443445447.
Where the class diverges: lixisenatide
Lixisenatide is the instructive exception to the boxed-warning pattern. Its FDA review positioned it pharmacologically closer to short-acting exenatide than to the long-acting agonists. Although 2-year rodent studies did show thyroid C-cell adenomas in mice (statistically significant only at the high dose) and a statistically significant increase in C-cell adenomas across all rat dose groups, plus low-incidence rat carcinomas, the reviewer emphasized very large exposure margins (on the order of 1,000-fold and higher) and marginal or undetectable GLP-1 receptor expression on human thyroid C-cells 472473484485487493. On that basis the program concluded the rodent C-cell profile most resembled short-acting exenatide immediate-release, and lixisenatide was treated more like a short-acting agent, unlike the long-acting agonists that carry the full boxed warning 485490494.
The synthesis for regulatory review
Across two decades of approvals, the GLP-1 receptor agonist class presents a coherent, reproducible safety signature: a rodent thyroid C-cell carcinogenicity signal of uncertain human relevance driving a class boxed warning and an MTC/MEN 2 contraindication; a shared cluster of Warnings and Precautions built around pancreatitis, gallbladder disease, volume-depletion-related acute kidney injury, hypoglycemia in combination with insulin secretagogues or insulin, and hypersensitivity; indication-linked additions for diabetic retinopathy (diabetes labels) and suicidal behavior and ideation (weight-management labels); and a dose-dependent gastrointestinal adverse-reaction burden that intensifies at the higher exposures used for obesity. The principal deviations, exenatide's rat-only carcinogenicity signal and lack of a mouse signal, albiglutide's antibody-limited rodent data and respiratory-weighted adverse reactions, and lixisenatide's short-acting positioning without the long-acting boxed-warning framing, are precisely the places where a reviewer comparing a new class entrant would concentrate scrutiny.